Ligand Pharmaceuticals Reports 34% Revenue Growth to $63.7 Million in Q2 2026

Ligand Pharmaceuticals Incorporated reported significant financial growth in its second quarter of 2026, with total revenues and income reaching $63.7 million, a 34% increase from $47.6 million in the same period last year. The company attributed this growth primarily to a 32% rise in royalties, which amounted to $48.0 million, driven by strong sales of products such as Filspari and Ohtuvayre. Year-to-date figures also reflected a positive trend, with total revenues increasing by 24% to $115.4 million compared to $93.0 million in the first half of 2025. The company’s net income for the quarter was $48.5 million, a substantial increase from $4.8 million in Q2 2025.

In terms of operational changes, Ligand's financial performance was bolstered by strategic investments and acquisitions. Notably, the company completed the acquisition of XOMA Royalty on July 14, 2026, which added seven commercial products and 14 late-stage development programs to its portfolio. This acquisition was funded through available cash and is expected to enhance Ligand's royalty streams significantly. Additionally, Ligand issued $700 million in convertible senior notes due 2031, which provided liquidity for further investments and share repurchases.

The company also reported a notable increase in research and development expenses, which rose by 123% to $14.7 million in Q2 2026, primarily due to a funding arrangement with Orchestra BioMed. General and administrative expenses increased by 44% to $29.1 million, reflecting transaction costs associated with the XOMA acquisition and higher employee-related costs. Despite these increases, total operating costs and expenses decreased by 26% year-to-date, indicating improved operational efficiency.

Ligand's balance sheet showed a significant increase in cash and cash equivalents, which rose to $1.0 billion as of June 30, 2026, compared to $174.9 million at the end of 2025. This increase was largely due to the proceeds from the convertible notes and the company's strategic financial management. The company also maintained a strong liquidity position with $124.4 million available under its revolving credit facility.

Looking ahead, Ligand expressed optimism about its growth trajectory, driven by its expanding portfolio of royalty assets and ongoing partnerships with leading biopharmaceutical companies. The company plans to continue investing in high-value royalty assets, with an annual investment target of $150 million to $250 million. However, management cautioned that future results may be influenced by various risks, including market conditions and the success of its partnered products.